TELO
NASDAQTelomir Pharmaceuticals Inc.
Price$1.27-0.13 (-8.96%)
2026-03-112026-06-12
News · 26 weeks33-56%
2025-12-212026-06-14
Mix2190d
- SEC Filings10(48%)
- Insider6(29%)
- Market5(24%)
Latest news
25 items- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes ModelInsulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-i
- INSIDERSEC Form 3 filed by new insider Mushak Andriy3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- INSIDERSEC Form 4 filed by CEO and Chairman Aminov Erez4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Whalen Matthew Pratt4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Macpherson Edward Clouston4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- INSIDERSEC Form 4 filed by Director Del Giudice Matthew Paul4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's DiseaseStudy Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model. MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporti
- SECSEC Form 10-Q filed by Telomir Pharmaceuticals Inc.10-Q - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerCompany Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC).This IND clearance enables the Compan
- INSIDERCEO and Chairman Aminov Erez acquired $10,028,003 worth of shares (7,319,710 units at $1.37) (SEC Form 4)4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newswire / April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ("TELI").The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, estab
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerFirst-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile.MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).The IND submission includes data from com
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECSEC Form 10-K filed by Telomir Pharmaceuticals Inc.10-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECSEC Form DEFM14A filed by Telomir Pharmaceuticals Inc.DEFM14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECSEC Form DEFA14A filed by Telomir Pharmaceuticals Inc.DEFA14A - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- SECTelomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)
- NEWSTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsIron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity.MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic drivers of cancer, today announced new in vitro data demonstrating that Telomir-1 (Telomir-Zn) induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer (TNBC).Iron-rescue experiments confirmed that the observed tumor cell mortality is iron-dependent, directly supporting Telomir-Zn's propos
TELO FAQ
6 questionsWhere does TELO stock trade?
Telomir Pharmaceuticals Inc. (TELO) is listed on NASDAQ.What sector and industry is TELO in?
Telomir Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Telomir Pharmaceuticals Inc. go public?
Telomir Pharmaceuticals Inc. (TELO) completed its IPO in 2024.What are analysts saying about TELO?
Telomir Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Rodman & Renshaw: Buy with a $1500.00 price target on 2025-02-21. Recent price targets cluster around $1500.00.What companies are similar to TELO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TELO side-by-side with any of them on Quantisnow.How can I track TELO on Quantisnow?
Quantisnow aggregates Telomir Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELO to receive live email and push alerts on every new disclosure.